Ouster (OUST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Charles Schwab Corporation came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of ...

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Humacyte, Inc. (HUMA) ended the recent trading session at $2.33, demonstrating a -3.72% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0 ...

Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

The Zacks Consensus Estimate projects NVIDIA’s earnings per share (EPS) to rise 42.1% in fiscal 2026 and 32.1% in fiscal 2027. Over the past seven days, earnings estimates have been revised upward, ...